Drugs That Could Slow Aging May Hold Promise for Protecting the Elderly from COVID-19

Drugs That Could Slow Aging May Hold Promise for Protecting the Elderly from COVID-19

Two recent human studies indicated that rapalogues increased resistance to the flu and decreased the severity of respiratory tract infections in older adults.

(© Solarisys/Adobe)


Keep Reading Keep Reading
Jamie Metzl And Nir Barzilai
Jamie Metzl is a member of the World Health Organization international advisory committee on human genome editing, a Singularity University Exponential Medicine faculty member, and the author of Hacking Darwin: Genetic Engineering and the Future of Humanity (paperback release April 7). @jamiemetzl. Nir Barzilai is a Professor of Medicine and Genetics and the Director of the Institute for Aging research at Albert Einstein College of Medicine, the Scientific Director of the American Federation for Aging Research and the author of Age Later: Healthspan, Lifespan, and the New Science of Longevity (June 2020). Dr. Nir Barzilai is the director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging. He is the Ingeborg and Ira Leon Rennert Chair of Aging Research, professor in the Departments of Medicine and Genetics, and member of the Diabetes Research Center and of the Divisions of Endocrinology & Diabetes and Geriatrics. Dr. Barzilai’s research interests are in the biology and genetics of aging.
A new type of cancer therapy is shrinking deadly brain tumors with just one treatment

MRI scans after a new kind of immunotherapy for brain cancer show remarkable progress in one patient just days after the first treatment.

Mass General Hospital

Few cancers are deadlier than glioblastomas—aggressive and lethal tumors that originate in the brain or spinal cord. Five years after diagnosis, less than five percent of glioblastoma patients are still alive—and more often, glioblastoma patients live just 14 months on average after receiving a diagnosis.

But an ongoing clinical trial at Mass General Cancer Center is giving new hope to glioblastoma patients and their families. The trial, called INCIPIENT, is meant to evaluate the effects of a special type of immune cell, called CAR-T cells, on patients with recurrent glioblastoma.

Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

Artificial Intelligence is getting better than humans at detecting breast cancer

A recent study in The Lancet Oncology showed that AI found 20 percent more cancers on mammogram screens than radiologists alone.

The Lancet Oncology

Since the early 2000s, AI systems have eliminated more than 1.7 million jobs, and that number will only increase as AI improves. Some research estimates that by 2025, AI will eliminate more than 85 million jobs.

But for all the talk about job security, AI is also proving to be a powerful tool in healthcare—specifically, cancer detection. One recently published study has shown that, remarkably, artificial intelligence was able to detect 20 percent more cancers in imaging scans than radiologists alone.

Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.